KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint.

Darren M Brenner, Andrea S Shin, Adam P Laitman, Jill K Deutsch, David C Kunkel

J Gastroenterol Hepatol 40(12) 2890-2897

PMID41214272
PMCIDPMC12666612
DOI10.1111/jgh.70119
发表日期2025-11-10
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。
摘要

摘要

BACKGROUND AND AIM: Irritable bowel syndrome with constipation (IBS-C) is characterized by multiple sensory symptoms, including abdominal pain, bloating, and bowel habit alterations. Therapeutic response should address all components. This study assesses a new exploratory trisymptom composite efficacy endpoint in an IBS-C population of young adults with bloating treated with plecanatide. METHODS: Pooled data were analyzed from two phase 3, randomized, double-blind trials. Patients (18-40 years) with IBS-C and baseline bloating (score ≥ 1) received plecanatide 3 mg or placebo for 12 weeks. The composite response definition was simultaneous improvement from baseline in three symptoms (abdominal pain, bloating, and complete spontaneous bowel movements [CSBMs]/week) for ≥ 6 of 12 weeks using several thresholds (≥ 2-point or ≥ 30% or ≥ 40% improvement in abdominal pain and bloating plus an increase of ≥ 1 or ≥ 2 CSBMs in the same week). RESULTS: Six hundred and five adults were included (plecanatide [n = 313]; placebo [n = 292]). Plecanatide/placebo baseline mean symptom scores were 6.2/6.4 for abdominal pain and 6.4/6.6 for bloating; both had a mean of 0.2 CSBMs/week. Significantly more patients in plecanatide versus placebo groups (p ≤ 0.01 for all comparisons) were trisymptom composite responders by several stringent thresholds, including ≥ 30% improvement in pain and bloating plus ≥ 1 CSBM/week increase (23.3% vs. 13.4%; p = 0.002) and ≥ 30% improvement in pain and bloating plus ≥ 2 CSBMs/week increase (19.5% vs. 8.9%; p < 0.001). Plecanatide was well tolerated. CONCLUSION: Plecanatide simultaneously and significantly improved combined symptoms of abdominal pain, bloating, and CSBM frequency at varying thresholds. Plecanatide is effective in improving global IBS-C symptoms in individuals with bloating. TRIAL REGISTRATION: ClinicalTrials.gov identifiers-NCT02387359 and NCT02493452.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 IBS‐C trisymptom composite responders in the (A) overall population and in patients with (B) mild or (C) moderate/severe bloating at baseline. IBS‐C = irritable bowel syndrome with constipation; CSBM = complete spontaneous bowel movement.
非 KM Figure
FIGURE 2FIGURE 2 LSM change from baseline in bloating in the (A) overall population and in patients with (B) mild or (C) moderate/severe bloating at baseline. * p < 0.05. † p ≤ 0.01. ‡ p ≤ 0.001. LSM = least‐squares mean.
非 KM Figure